Biotech · Public company · Philadelphia, PA, US
Cabaletta Bio, Inc.
Ticker CABA · SEC CIK 0001759138
Track this companyFree. Adds Cabaletta Bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials65 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline7
- CABA-201Phase 3 · Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- CABA-201 following preconditioning with fludarabine and cyclophosphamidePhase 3 · Idiopathic Inflammatory MyopathyClinicalTrials.gov · fetched Nov 12, 2026
- CABA-201Phase 2 · Pemphigus VulgarisClinicalTrials.gov · fetched Nov 12, 2026
- CABA-201Phase 2 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- CABA-201Phase 2 · Generalized Myasthenia Gravis (gMG)ClinicalTrials.gov · fetched Nov 12, 2026
- DSG3-CAARTPhase 2 · Pemphigus VulgarisClinicalTrials.gov · fetched Nov 12, 2026
- MuSK-CAARTPhase 1 · MuSK Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia GravisPHASE1_PHASE2 · RECRUITING · started Dec 17, 2024ClinicalTrials.gov NCT06359041 · fetched Nov 12, 2026
- RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic SclerosisPHASE2_PHASE3 · RECRUITING · started Jul 2, 2024ClinicalTrials.gov NCT06328777 · fetched Nov 12, 2026
- RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusPHASE1_PHASE2 · RECRUITING · started Feb 16, 2024ClinicalTrials.gov NCT06121297 · fetched Nov 12, 2026
- RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory MyopathyPHASE2_PHASE3 · RECRUITING · started Dec 20, 2023ClinicalTrials.gov NCT06154252 · fetched Nov 12, 2026
- Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia GravisPHASE1 · COMPLETED · started Nov 23, 2022ClinicalTrials.gov NCT05451212 · fetched Nov 12, 2026
- A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)PHASE1_PHASE2 · RECRUITING · started Sep 29, 2020ClinicalTrials.gov NCT04422912 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 14, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026